• treatment
  • Most of them were previously on zidovudine monotherapy or dual combination therapy, and as many as 34% remained on this suboptimal therapy, which is an unacceptable number of patients, taking into account that this modality of treatment is unable to suppress viral replication, and can lead to drug resistance and the limitation of future options. (natap.org)